enVastTM
REDEFINING CORONARY THROMBECTOMY
ENVAST EFFECTIVE & SAFE
Equipped with Drop Zone technology, the enVast coronary thrombectomy system has been proven to remove large thrombus burden (LTB) and create immediate reperfusion in 85% of cases. (n = 61)
EFFECTIVE
(core-lab adjudicated)
72%
MBG 2-3 after enVast
85%
immediate reperfusion at enVast deployment
90%
TIMI 3
after enVast
98%
TIMI 3
end of PCI
SAFE
Procedural Outcomes
0
- coronary dissection
- coronary perforation
- cardiac tamponade
- life-threatening arrhythmia
- flow-limiting spasm
1.6%
coronary embolization (all resolved)
Clinical Outcomes – 30 Days
0
- stroke
- recurrent MI
- bleeding BAARC 3 or 5
3.3%
cardiovascular death (patients were in cardiogenic shock at admission)
ENVAST DESIGNED FOR RAPID, HI-FLOW REPERFUSION
Comprehensive Clot Removal
- full range of clots
- larger volumes of clot
Proximal-to-Distal
Clot Engagement
designed to mitigate distal embolization and stroke risk
Engineered for
Vessel-wall Conformity
- adapts to anatomical challenges
- allows complete clot integration
INVESTING IN CLINICAL SCIENCE
Vesalio is sponsoring the NATURE study, a randomized, multi-center clinical trial, comparing the safety and efficacy of enVast™ as an adjunct to conventional intervention versus the standard of care in MI patients with large thrombus burden.
clinicaltrials.gov ID NCT04969471
“enVast could provide a new therapeutic opportunity for myocardial infarct patients with large thrombus burden, who still represent a major challenge for procedural success and long-term outcomes.”
Prof Dr Marco Valgimigli
Istituto Cardiocentro Ticino, Lugano, Switzerland
CHOOSE
TO REMOVE